Description du projet
L’immunisation passive en tant que stratégie pour traiter l’infection à coronavirus
Il est urgent de développer l’immunisation passive de courte durée en tant que thérapie anti-COVID-19, afin d’aplanir la courbe d’infection et de gagner du temps pour mettre en place des approches d’immunité de groupe. La stratégie nécessite l’exploitation de l’hétérogénéité extrême des réponses immunitaires antivirales humaines. La société irlandaise Remedy Biologics a développé une plateforme visant à analyser rapidement et simultanément des millions de cellules immunitaires produisant des anticorps à partir d’un échantillon individuel. Cela pourrait permettre d’identifier les meilleurs anticorps pour les systèmes immunitaires des personnes en convalescence suite à la COVID-19, afin de permettre de créer des thérapies passives pour les patients gravement malades. Le projet RapCo-19, financé par l’UE, vise à combiner des technologies de découverte innovantes pour créer une plateforme d’identification et de production rapides d’anticorps neutralisants antiviraux contre la COVID-19.
Objectif
The SARS-CoV-2 pandemic requires the most serious and rapid healthcare response seen in modern history. The lag time between the emergence of the pathogen and the implementation of a licensed vaccine still remains an obstacle for prophylactic measures. In addition, how long immunity lasts for following COVID-19 infection is a big unknown. The development of immunity to the currently circulating SARS-CoV2 may not provide sterilising protection against subsequent coronavirus infections. If this were to be confirmed, it would add to the challenge of managing the pandemic.
Short-lived passive immunisation with an anti-COVID-19 therapy is immediately required to treat infected patients and to ‘flatten the infection curve’ and to provide time for ‘herd immunity’ approaches. Devising an effective strategy requires an approach that is designed to exploit the extreme heterogeneity of the human anti-viral immune response.
RemedyBio’s Nanoreactor technology is such a system. It is the result of a 5-year research programme to develop a platform to rapidly and simultaneously analyse millions of single antibody-producing immune cells from an individual sample. In the context of COVID-19, this presents an opportunity to rapidly identify the best antibodies from the immune systems of COVID-19 convalescent patients from which to create a rapid passive therapeutic for those that are critically ill from the virus.
Based on records from 1918/1919, it is plausible for the COVID-19 pandemic to wane in the late spring (in Europe), and come back as a second wave in the winter, which, as was the case in 1918, could be even worse than what we're facing now. COVID-19 is a global health problem and we need to be ready for this. This project is designed to combine novel discovery and delivery technologies to form a platform to rapidly identify, produce and deliver anti-viral neutralising antibodies to COVID-19.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
SME - SME instrumentCoordinateur
A84R970 ASHBOURNE CO MEATH
Irlande
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.